Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning